| Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC (NCT05332925) | Jun Zhang, MD, PhD | 2022-07-21 |
| Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma (NCT05303493) | Centre hospitalier de l'Université de Montréal (CHUM) | 2022-06-29 |
| A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) (NCT05429320) | Memorial Sloan Kettering Cancer Center | 2022-06-15 |
| Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities (NCT05311709) | Vestre Viken Hospital Trust | 2022-05-30 |
| Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check) (NCT05383001) | AIO-Studien-gGmbH | 2022-05-20 |
| Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC (NCT04467723) | University of Kansas Medical Center | 2022-05-18 |
| SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors (NCT05387044) | Zhejiang Cancer Hospital | 2022-05-01 |
| A Study to Investigate LYL797 in Adults With Solid Tumors (NCT05274451) | Lyell Immunopharma, Inc. | 2022-03-29 |
| Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC (NCT04136535) | Fudan University | 2021-11-18 |
| Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) (NCT05281406) | Goethe University | 2021-11-12 |
| Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer (NCT05132218) | Peking University Cancer Hospital & Institute | 2021-10-19 |
| Primary Tumor Resection With EGFR TKI for Stage IV NSCLC (NCT05215548) | National Taiwan University Hospital | 2021-09-27 |
| Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (NCT04467801) | Jun Zhang, MD, PhD | 2021-09-14 |
| Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC (NCT05055583) | Tang-Du Hospital | 2021-08-31 |
| Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor (NCT04932343) | Samsung Medical Center | 2021-06-01 |
| SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs (NCT04764214) | Fudan University | 2021-03-01 |
| AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) (NCT04364620) | Alethia Biotherapeutics | 2021-02-23 |
| Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy (NCT04676386) | Addario Lung Cancer Medical Institute | 2021-02-01 |
| SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors (NCT04767009) | Fudan University | 2021-01-01 |
| Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy (NCT04613804) | Fujian Cancer Hospital | 2020-12-01 |
| Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC (NCT04507906) | Shanghai Chest Hospital | 2020-11-02 |
| A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC (NCT04521075) | Ella Therapeutics Ltd | 2020-11-01 |
| Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2 (NCT04604470) | Maastricht University | 2020-10-20 |
| Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC (NCT04549428) | Oncology Institute of Southern Switzerland | 2020-10-01 |
| Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC (NCT04507217) | Sun Yat-sen University | 2020-09-15 |
| Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC (NCT04768491) | Peking Union Medical College | 2020-09-01 |
| Prospective Observation of Failure Patterns in NSCLC Treated With ICIs (NCT04492969) | Fudan University | 2020-09-01 |
| Lung Cancer Registry (NCT04654364) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2020-08-18 |
| Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC) (NCT04636775) | Jun Zhang, MD, PhD | 2020-07-29 |
| Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (NCT04223596) | Fundación GECP | 2020-05-04 |
| PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC (NCT04284202) | The Affiliated Hospital of Qingdao University | 2020-03-01 |
| Plasma-Adapted First-Line Pembro In NSCLC (NCT04166487) | Julia K. Rotow, MD | 2020-01-13 |
| Camrelizumab Combined With Local Treatment in NSCLC Patients With BM (NCT04291092) | Zhejiang Cancer Hospital | 2020-01-01 |
| Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer (NCT04102982) | Shandong Provincial Hospital | 2019-11-01 |
| SRS Sequential Sindilimab in Brain Metastasis of NSLSC (NCT04180501) | Xiaorong Dong | 2019-11-01 |
| SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC (NCT04106180) | Fudan University | 2019-09-30 |
| A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (NCT04042558) | Centre Francois Baclesse | 2019-09-26 |
| Phase 2 Study of Dacomitinib in NSCLC (NCT04027647) | National Cancer Centre, Singapore | 2019-09-11 |
| Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC (NCT04116918) | Baodong Qin | 2019-09-01 |
| Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer (NCT03777124) | Jiangsu HengRui Medicine Co., Ltd. | 2019-07-11 |
| IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study (NCT03705403) | Maastricht University Medical Center | 2019-04-04 |
| FGFR Inhibitor in FGFR Dysregulated Cancer (NCT03827850) | Lung Cancer Group Cologne | 2019-03-25 |
| Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (NCT03805841) | Rain Oncology Inc | 2019-03-13 |
| Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung (NCT03808662) | Memorial Sloan Kettering Cancer Center | 2019-01-16 |
| Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations (NCT05701787) | Shanghai Chest Hospital | 2019-01-01 |
| 1st Line Durvalumab in PS 2 NSCLC Patients (NCT03620669) | Swiss Cancer Institute | 2018-12-04 |
| Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer (NCT03713944) | Nasser Hanna | 2018-11-15 |
| 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC (NCT03564197) | The Netherlands Cancer Institute | 2018-10-25 |
| Alectinib-induced Endocrine Toxicity (NCT06339554) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2018-10-12 |
| Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors (NCT03647956) | The University of Hong Kong | 2018-10-01 |
| Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study (NCT03594682) | Beijing Chest Hospital | 2018-08-01 |
| T790M Mutation Testing in Blood by Different Methodologies (NCT03363139) | Spanish Lung Cancer Group | 2018-03-01 |
| The Role of Microbiota on the Development of Lung Cancer (NCT03454685) | Xiaorong Dong | 2018-01-30 |
| Early Response Evaluation in NSCLC Patients Treated With Immunotherapy (NCT04082988) | The Netherlands Cancer Institute | 2018-01-23 |
| Factors Determining the Prognosis in NSCLC Stage IV (NCT04306094) | Instituto do Cancer do Estado de São Paulo | 2017-11-01 |
| Study of AGEN1884 With Pembrolizumab in 1L NSCLC (NCT03411473) | Agenus Inc. | 2017-10-04 |
| Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT03184571) | BerGenBio ASA | 2017-10-02 |
| Neo-MASCT Immunotherapy for Advanced NSCLC. (NCT03205930) | The First People's Hospital of Lianyungang | 2017-08-01 |
| Phase I Study of SPH1188-11 in NSCLC (NCT03231475) | Shanghai Pharmaceuticals Holding Co., Ltd | 2017-07-21 |
| To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC (NCT03130829) | Hi-Q Marine Biotech International, Ltd. | 2017-04-26 |
| Cachexia in NSCLC Patients: Diagnosis, Characterization, Prognosis, Functional and Skeletal Muscle Implications (NCT03960034) | Instituto do Cancer do Estado de São Paulo | 2017-04-10 |
| EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide (NCT03341494) | Fujian Cancer Hospital | 2017-04-01 |
| MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC (NCT04633564) | Mylan Pharmaceuticals Inc | 2017-01-21 |
| Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients (NCT04076228) | Kiang Wu Hospital | 2017-01-01 |
| Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer (NCT06207292) | Radiotherapy Oncology Centre "Santa Maria" Hospital | 2016-12-01 |
| Donation of Post Mortem Tumor Tissues (NCT03385980) | Niguarda Hospital | 2016-02-11 |
| Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR) (NCT02735850) | Maastricht Radiation Oncology | 2015-12-01 |
| Genomic Study in Non-small Cell Lung Cancer Brain Metastasis (NCT04745715) | National Cheng-Kung University Hospital | 2011-01-01 |
| Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer (NCT03515252) | Ivy Life Sciences, Co., Ltd | 2005-04-26 |